GlycoMimetics, Inc. (GLYC) Thursday said the Phase 1a study of its drug candidate GMI-1687 met its primary goal.
In the Phase 1a study, healthy volunteers were randomized to receive either GMI-1687 or placebo. The study met its primary and secondary endpoints of safety, tolerability and pharmacokinetics. Further, there were no dose limiting toxicities or safety signals.
GMI-1687 is being developed for the treatment of inflammatory diseases, with initial focus on sickle cell disease (SCD), the most common inherited blood disorder in the United States.
For comments and feedback: editorial@rttnews.com